POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or S\u00e9zary syndrome after at least one prior systemic therapy.<\/p>\n
Poteligeo (mogamulizumab-kpkc injection) for intravenous use Initial U.S. Approval: 2018
\nTo access mogamulizumab-kpkc injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Poteligeo (mogamulizumab) is a medication used to treat adult patients with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS) after at least one prior systemic therapy.<\/p>\n
Disease Indications-Lymphoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cMogamulizumab-kpkc Injection\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Kyorin Pharmaceuticals Co
\nUsage-Intravenous
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Therapeutic Goods Administration (TGA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n